Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug PharmaphorumCelcuity has won FDA approval for gedatolisib - its first product - as a treatment for patients with a particular form of breast cancer.OncologyRead full story pharminent July 15, 2026 (Last updated: July 16, 2026) Pharmaphorum Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of breast cancer. Oncology Read full story Post navigation Previous: Biogen’s Tau-Targeting Alzheimer’s Data Show Promise — and Raise QuestionsNext: AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026